CEO and President Joe Payne outlined the company’s current focus on messenger RNA (mRNA) therapeutics, emphasizing a leaner operating profile and a near-term set of clinical and regulatory milestones ...
"I haven’t returned to the deathbed confessions of ★ since 2016. Instead, I’ve spent the last decade trying to remember Bowie ...
Preliminary Q4 2025 PEMGARDA® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth ...
In a move that could impact vaccine-makers like Merck & Co. Inc. MRK, GSK plc GSK, the U.S. government has decided to ...
Introduction Globally, half of all 6.2 million deaths in children are caused by acute illnesses which can be prevented if ...
JOHNSON SPACE CENTER — Even though the IM-1 mission’s lunar lander Odysseus tipped over after landing on the moon last week, the company’s CEO called it a “successful mission” during a press ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results